Documente Academic
Documente Profesional
Documente Cultură
Tumor Markers
Clinical Background
Tumor and genetic markers may be useful in the diagnosis, treatment, monitoring and prognostication
®
of specific tumors. Available markers include those in the following table (most are available at ARUP
Laboratories); for recommendations, see the Diagnosis tab. The information that follows is general in nature;
for specific information regarding use and interpretation of various markers and tests, consultation with a
pathologist is highly advised.
Tumor Markers
Tumor markers - #
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
5-HIAA Carcinoid U
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - A
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
ACTH Neuroendocrine T B
AFP-L3% HCC B
APC Colorectal T
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - B
Marker Methodology
Malignancy
Molecular FISH IHC Other
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 1 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Stain
BF-1 Lymphoma T
BOB-1 Lymphoma T
®
BTA stat (Bladder Bladder U
tumor antigen)
BTA TRAK
® Bladder U
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - C
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
CA 27.29 Breast B
CA 72-4 Gastric B
C-peptide Neuroendocrine B
Calcitonin T B
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 2 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Neuroendocrine,
medullary thyroid
carcinoma (MTC)
Calcium Parathyroid B
CD4 Lymphoma T
CD7 Lymphoma T
CD21 Lymphoma T
CD38 CLL T B
CD52 Lymphoma T
CD57 Leukemia/lymphoma T
CD79A B-ALL T
CD117 (c-KIT )
1 Gastrointestinal T
1
T
1 B
1
stromal tumor (GIST) ,
leukemia/lymphoma,
melanoma
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 3 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Chromogranin A Neuroendocrine, T B
neuroblastoma, small
cell lung (SCLC)
CK 5,6 Mesothelioma T
CK 7 Colorectal, NSCLC T
CK 20 Bladder, colorectal, T
lung
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - D
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
DEK-NUP214 AML B
t(6;9)(p23;q34)
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 4 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Tumor markers - E
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
EBV-EBER Lymphoma T
EML4-ALK NSCLC T
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - F
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - G
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
Glucagon Glucagonoma T B
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 5 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Granzyme B Lymphoma T
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - H
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
Hercept/HER2 Breast T T T B
HER2/neu
HE4 Ovarian B
1
cervical brush ; ISH on neck
2
tissue )
HTLV Lymphoma T
HVA Neuroblastoma U
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - I
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
IGF-1 Neuroendocrine B
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 6 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
™
ImmunoCyt /uCyt+
™ Bladder U
Insulin Insulinoma T B
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - J
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - K
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - L
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
LH/FSH Neuroendocrine T B
(pituitary)
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 7 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - M
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
Melan A Melanoma T
Mesomark
® Mesothelioma B
MPO Breast T
(myeloperoxidase)
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - N
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
NMP22
® Bladder U
N-myc Neuroblastoma T
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 8 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - O
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - P
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
PAM50 Breast T
p16 Bladder T
PAX3-FKHR Rhabdomyosarcoma T
t(2;13)(q35;q14)
PAX7-FKHR
t(1;13)(p36;q14)
PIK3CA T
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 9 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
PLAP Seminoma, T
germinoma, ovarian
Proinsulin Insulinoma T B
Prolactin Neuroendocrine T B
(pituitary)
PSA Prostate T B
PTH Parathyroid B
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - R
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
RB-1 Bladder T
RET (MEN2a ,
1
Neuroendocrine ,
1 B
2 1 2
MEN2b ) parathyroid , MTC
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - S
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
SKp2 Breast T
SMAD4 Colorectal B
Serotonin Carcinoid B
Somatostatin Somatostatinoma T B
Survivin Bladder T
Synaptophysin Neuroendocrine T
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - T
Marker Methodology
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 10 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
TA90-IC Melanoma T B
TdT ALL T
TIA-1 Lymphoma T
TSH Neuroendocrine T B
(pituitary), thyroid
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - U
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
UGT1A1 Colorectal B
uPA/PAI-1 Breast T
™ 1 2 1
UroVysion Bladder , pancreatic U
(bladder cancer, T
2
pancreatobiliary FISH)
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - V
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
Villin Adenocarcinoma T
(pancreatic,
gastrointestinal)
VMA Neuroblastoma U
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - W
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 11 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Tumor markers - Z
Marker Methodology
Malignancy
Molecular FISH IHC Other
Stain
ZAP-70 CLL T B
B = blood (serum, plasma or whole), T = tissue (includes bone marrow), U = urine, F = fluid
Diagnosis
Tumor Markers and Genetic Markers – Use for Specific Malignancy
The following information is from multiple guideline sources as recommendations for use of tumor markers
and genetic markers.
Gastrointestinal
Tumor Type Marker Recommended Use Recommending
Organizations*
Hepatic AFP Monitoring ACS, NCCN, ESMO,
NACB
Early detection in high-risk ACS, NCCN, ESMO,
patients NACB
AFP-L3% Monitoring, early detection NACB
in high-risk patients,
prognosis
DCP Monitoring, early detection NACB
in high-risk patients,
prognosis
Gastric No markers with good None available NACB
evidence
Helicobacter pylori Environmental risk factor NCCN
E-Cadherin mutations Risk factor in hereditary NCCN
forms
Pancreatic CA19-9 Monitoring NCCN, ESMO, NACB
(ductal adenocarcinoma) Diagnosis NCCN, NACB
Colorectal CEA Monitoring ASCO, NACB, ESMO,
NCCN
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 12 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Neuroendocrine
Tumor Type Marker Recommended Use Recommending
Organizations
All neuroendocrine tumors Chromogranin A (serum, Diagnosis NCCN, ESMO, NACB
IHC) Recurrence NACB
Monitoring NACB
Synaptophysin (serum, Diagnosis NCCN
IHC)
Prolactin (serum, IHC) Diagnosis NCCN
CK (Cytokeratin) (serum) Diagnosis NCCN
Ki-67 (MIB-1) (IHC) Diagnosis NCCN
Carcinoid 5-HIAA (urine) Diagnosis NCCN, ESMO, NACB
Monitoring for specific NCCN, ESMO, NACB
tumor
Serotonin (serum) Diagnosis NACB
Chromogranin A (serum, Diagnosis and monitoring NCCN
IHC)
Gastrin (serum, IHC) Diagnosis and monitoring NCCN
Pancreatic polypeptide Diagnosis and monitoring NCCN
(serum, IHC)
Gastrinoma Gastrin (serum, IHC) Diagnosis and monitoring NCCN, ESMO, NACB
Glucagonoma Glucagon (serum, IHC) Diagnosis and monitoring NCCN, ESMO, NACB
Pheochromocytoma Metanephrines (plasma, Diagnosis and monitoring NCCN, ESMO, NACB
urine)
Catecholamines (urine) Diagnosis and monitoring NCCN, ESMO, NACB
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 13 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Insulinoma Proinsulin (serum, IHC) Diagnosis and monitoring NCCN, ESMO, NACB
Insulin (serum, IHC) Diagnosis and monitoring NCCN
C-peptide (serum, IHC) Diagnosis and monitoring NCCN
Pituitary Growth hormone (serum, Diagnosis and monitoring NCCN, ESMO, NACB
IHC)
IGF-1 (serum) Diagnosis and monitoring NCCN
Prolactin (serum, IHC) Diagnosis and monitoring NCCN
LH/FSH (serum, IHC) Diagnosis and monitoring NCCN
TSH (serum, IHC) Diagnosis and monitoring NCCN
Alpha subunit (serum, Diagnosis and monitoring NCCN
IHC)
ACTH (serum, IHC) Diagnosis and monitoring NCCN
VIPoma VIP (serum, IHC) Diagnosis and monitoring NCCN, ESMO, NACB
Pancreatic Pancreatic polypeptide Diagnosis and monitoring NCCN, ESMO, NACB
neuroendocrine (serum, IHC)
carcinoma Calcitonin (serum, IHC) Diagnosis and monitoring NCCN
PTH-related peptide Diagnosis and monitoring NCCN
(serum)
PTH (IHC) Diagnosis and monitoring NCCN
Somatostatin (serum, Diagnosis and monitoring NCCN
IHC)
NCCN = National Comprehensive Cancer Network, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical
Biochemistry
Lung
Tumor Type Marker Recommended Use Recommending
Organizations*
Small cell NSE (serum, IHC) Monitoring ACS, NACB
(SCLC) Prognosis NACB
Chromogranin A Prognosis NACB
Non-small cell CEA, SCC Ag Monitoring, prognosis, NACB, ASCO
(NSCLC) detecting relapse
CK19 fragment Prognosis ASCO
(CYFRA 21-1),
Mesothelioma Soluble mesothelin related Monitoring IMIG, NACB, NCCN
®
peptides (Mesomark )
CK 5,6 Diagnosis NCCN
CEA Diagnosis NCCN
b72.3 Diagnosis NCCN
WT-1 Diagnosis NCCN
TTF-1 Diagnosis NCCN
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 14 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Female gynecologic/genitourinary
Tumor Type Marker Recommended Use Recommending
Organizations
Breast Estrogen, progesterone Predict hormone response ASCO, ESMO, NCCN,
receptor (tissue) NACB
Prognosis ASCO (do not use alone),
NCCN, NACB (do not use
alone), ACS
b72.3 Diagnosis NCCN
HER, HER2, HER-2/neu Predict response to ASCO, ESMO, ACS,
(tissue) Herceptin NCCN, NACB
Prognosis NCCN, NACB
Predict response to ASCO, NCCN, NACB
anthracyclines
uPA/PAI-1 (tissue) Prognosis ASCO, ACS, NACB
CA 15-3, CA 27-29 Monitoring advanced ASCO, ESMO, NACB,
disease ACS
CEA Monitoring advanced ASCO, NACB
disease
BRCA1, BRCA2 Identifying high-risk ASCO, NCCN, NACB
patients
HER-2/neu (serum) Monitoring, prognosis NACB
p53 Prognosis NACB
Cervical HPV Risk assessment NCCN, NACB
SCC Ag Monitoring NACB
Ovarian CA 125 Monitoring ESMO, NACB, NCCN
Differential diagnosis is NACB, NCCN
suspicious pelvic mass
Detection of recurrence ESMO, NACB, NCCN
Prognosis ESMO, NACB
βhCG Diagnosis, recurrence NCCN
Gestational trophoblastic βhCG Monitoring ACS, NACB, NCCN
Diagnosis ACS, NACB, NCCN
Bladder BTA stat ,
® Monitoring, early detection ACS, NACB, NCCN
®
BTA TRAK ,
®
NMP22 ,
™, ™
UroVysion ImmunoCyt
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 15 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ASCO = American Society of Clinical Oncology, ESMO = European Society of Medical Oncology, NCCN = National Comprehensive
Cancer Network, NACB = National Academy of Clinical Biochemistry, ACS = American Cancer Society
Male Genitourinary
Tumor Type Marker Recommended Use Recommending
Organizations*
Prostate PSA Screening ACS, AUA, EAU, ESMO,
NACB, NCCN
Staging and prognosis AUA, EAU, ESMO,
NCCN, NACB
Monitoring AUA, EAU, ESMO,
NCCN, NACB
Follow-up and negative NCCN, NACB
biopsy
PCA3 Screening NACB
Bladder BTA stat ,
® Monitoring, diagnosis ACS, NACB, NCCN
®
BTA TRAK ,
®
NMP22 ,
™
UroVysion ,
™
ImmunoCyt
Germ cell (testicular) βhCG and AFP Diagnosis and ASCO, EAU, ESMO,
differential diagnosis of NACB, NCCN
nonseminomatous germ
cell cancer of the testes
Staging and prognosis ASCO, EAU, ESMO,
NACB, NCCN
Monitoring ASCO, EAU, ESMO,
NACB, NCCN
Detecting recurrence ASCO, EAU, ESMO,
NACB, NCCN
LD Diagnosis ASCO, EAU, ESMO,
NACB, NCCN
Staging and prognosis ASCO, EAU, ESMO,
NACB, NCCN
Monitoring ASCO, EAU, ESMO,
NACB, NCCN
Detecting recurrence ASCO, EAU, ESMO,
NACB, NCCN
ACS = American Cancer Society, ASCO = American Society of Clinical Oncology, AUA = American Urological Association, EAU =
European Association of Urologists, ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry,
NCCN = National Comprehensive Cancer Network
Brain
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 16 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Soft Tissue/Sarcomas
Tumor Type Marker Recommended Use Recommending
Organizations
Ewing sarcoma EWSR1 – Ewing sarcoma Diagnosis ESMO, NACB, NCCN
by RT-PCR
EWSR1 rearrangement by Diagnosis NACB, NCCN
FISH
Synovial SYT, SYT-SSX Diagnosis NACB, NCCN
SYT rearrangement by Diagnosis NACB, NCCN
FISH
Rhabdomyosarcoma PAX-FKHR Diagnosis NACB, NCCN
Kaposi sarcoma HHV8 Diagnosis NACB, NCCN
ESMO = European Society of Medical Oncology, NACB = National Academy of Clinical Biochemistry, NCCN = National Comprehensive
Cancer Network
Lymphoma
Tumor Type Marker Recommended Use Recommending
Organizations
B-cell and T/NK-cell IGH/BCL2 Diagnosis and NCCN, NACB
differentiation of
lymphomas
IGH/CCND1 Diagnosis of mantle cell NCCN, NACB
(MCL) subtype
API2-MLT1 t(11;18) Diagnosis of a subset of NCCN, ESMO, NACB
MALT lymphomas
ALK rearrangements Diagnosis and NCCN, NACB
differentiation
c-Myc (MYC Diagnosis and NCCN
rearrangements [t(8;14)]) differentiation of Burkitt
lymphoma
CD2, CD3, CD4, CD5, Diagnosis and NCCN, NACB
CD7, CD8, CD10, CD14, differentiation
CD15, CD19 (BCL-6),
CD20, CD21, CD23,
CD33, CD45 (LCA),
CD52, CD56, CD57,
CD64, CD79a, CD117 (c-
KIT), CD138
Cyclin D1, SP4 Diagnosis of MCL and NCCN
t(11;14) multiple myeloma
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 17 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Leukemia
Tumor Type Marker Recommended Use Recommending
Organizations
ALL BCR/ABL1 Diagnosis, prognosis, NACB
monitoring
c-Myc (MYC Diagnosis and NCCN
rearrangements [t(8;14)]) differentiation
ETV6/RUNX1(TEL/AML1) Diagnosis, prognosis, NACB
t(12;21)(p13;q22) monitoring
E2A/PBX1 Diagnosis, prognosis, NACB
t(1;19)(q23;p13.3) monitoring
(TCF3-PBX1)
Hyperdiploidy (+4, +10, Diagnosis, prognosis, NACB
+17) monitoring
MLL rearrangement Diagnosis, prognosis, NACB
monitoring
IGH rearrangement Diagnosis, prognosis, NACB, NCCN
monitoring
AML RUNX1/RUNX1T1 t(8;21) Diagnosis of ESMO, NACB
prognostically important
genetic subtype
FLT3-ITD Prognosis ESMO, NACB
Philadelphia Diagnosis and prognosis NCCN
chromosome t(9;22)
inv(16) or t(16;16) of Diagnosis and prognosis ESMO, NACB, NCCN,
CBFβ/MYH11 WHO
AML1/ETO t(8;21) Diagnosis and prognosis NCCN, WHO
MLLT3-MLL t(9;11) Prognosis NCCN
c-KIT (CD117) Prognosis NCCN
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 18 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Myeloproliferative Neoplasms
Tumor Type Marker Recommended Use Recommending
Organizations
Myeloproliferative JAK2 Diagnosis NACB
Myeloproliferative with PDGFRα, PDGFRβ and Diagnosis NACB, WHO
associated eosinophilia FGFR1 rearrangements
by FISH
NACB = National Academy of Clinical Biochemistry, WHO = World Health Organization
Childhood Tumors
Tumor Type Marker Recommended Use Recommending
Organizations
Neuroblastoma NSE Prognosis NACB
N-myc Prognosis NACB
HVA, VMA, Diagnosis, monitoring NACB
catecholamines
Childhood leukemia MLL-AF4 rearrangement Diagnosis NACB
BCR/ABL1 Diagnosis, prognosis, NACB, NCCN
monitoring
ETV6/RUNX1(TEL/AML1) Diagnosis, prognosis, NACB, ASCO
t(12;21)(p13;q22) monitoring
Hyperdiploidy (+4, +10, Diagnosis, prognosis, NACB
+17) monitoring
MLL-AF4, t(4;11) Diagnosis, prognosis, NACB
monitoring
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 19 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ASCO = American Society of Clinical Oncology, NACB = National Academy of Clinical Biochemistry, NCCN = National Comprehensive
Cancer Network
Skin
Tumor Type Marker Recommended Use Recommending
Organizations
Melanoma TA90-IC Monitoring, prognosis ACS, NACB
S-100, HMB45 (gp100) Diagnosis, usually used in ACS, NACB
combination
S-100B (serum) Monitoring, prognosis ACS, NACB
c-Kit Response to therapy ACS
ACS = American Cancer Society, NACB = National Academy of Clinical Biochemistry
Thyroid/Parathyroid
Tumor Type Marker Recommended Use Recommending
Organizations
Well-differentiated BRAF V600E (tissue) Diagnosis NACB
BRAF V600E (serum) Prognosis NACB
Thyroglobulin (serum) Diagnosis, monitoring NCCN, AACE, NACB
Thyroglobulin (IHC) Diagnosis NACB
Medullary thyroid Calcitonin Monitoring, diagnosis NCCN, AACE, NACB
carcinoma CEA Diagnosis, monitoring NCCN, NACB
Parathyroid PTH, calcium Diagnosis, monitoring NCCN, NACB
PTH-related peptide Diagnosis and monitoring NCCN
Hereditary forms HRPT2 Genetic risk assessment NACB
for parathyroid
carcinoma or primary
hyperparathyroidism
MEN1 Genetic risk assessment AACE, NACB, NCCN
for MEN1
RET Genetic risk assessment AACE, NACB, NCCN
for MEN2
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 20 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
NCCN = National Comprehensive Cancer Network, AACE = American Association of Clinical Endocrinologists, NACB = National Academy
of Clinical Biochemistry
Lab Tests
Indications for Laboratory Testing
Tests generally appear in the order most useful for common clinical situations. For test-specific information, refer to the
test number in the ARUP Laboratory Test Directory on the ARUP Web site at www.aruplab.com.
Gastrointestinal
Test Name and Number Comments
Alpha Fetoprotein, Serum HCC tumor marker
(Tumor Marker) 0080428
Method:
Electrochemiluminescent
Immunoassay
PIK3CA Mutation HCC and colorectal tumor marker
Detection 2004510
Method:
Polymerase Chain
Reaction/Pyrosequencing
Alpha Fetoprotein, Total Risk assessment for development of HCC in patients with chronic liver diseases
and L3 Percent Effective
Immediately 0081208
Method: Liquid-Phase
Binding Immunoassay
Alpha-1-Fetoprotein (AFP) Gastrointestinal tumor marker
by Immunohistochemistry
2003436
Method:
Immunohistochemistry
Des-gamma-carboxy Tumor marker for HCC monitoring, prognosis and early detection in high-risk
Prothrombin 0081312 patients
Method: Liquid-Phase
Binding Immunoassay
Cancer Antigen-GI (CA Pancreatic cancer tumor marker
19-9), Body Fluid 0020746
Method:
Electrochemiluminescent
Immunoassay
Cancer Antigen-GI (CA Tumor marker for pancreatic ductal adenocarcinoma
19-9) 0080461
Method:
Electrochemiluminescent
Immunoassay
Pancreatobiliary FISH Pancreatic cancer tumor marker
2002461
Method:
Fluorescence in situ
Hybridization/Automated
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 21 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 22 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 23 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
by Immunohistochemistry
2003920
Method:
Immunohistochemistry
Villin by Gastrointestinal tumor marker
Immunohistochemistry
2004178
Method:
Immunohistochemistry
CDX2 by Gastrointestinal tumor marker
Immunohistochemistry
2003821
Method:
Immunohistochemistry
Muc-1 by Gastrointestinal tumor marker
Immunohistochemistry
2004002
Method:
Immunohistochemistry
Muc-2 by Gastrointestinal tumor marker
Immunohistochemistry
2004005
Method:
Immunohistochemistry
Muc-4 by Gastrointestinal tumor marker
Immunohistochemistry
2004008
Method:
Immunohistochemistry
Muc 5AC by Gastrointestinal tumor marker
Immunohistochemistry
2003999
Method:
Immunohistochemistry
Breast Carcinoma b72.3 Gastrointestinal tumor marker
by Immunohistochemistry
2003445
Method:
Immunohistochemistry
Gastrin by Gastrointestinal tumor marker
Immunohistochemistry
2003896
Method:
Immunohistochemistry
p27 (Kip1) by Gastrointestinal tumor marker
Immunohistochemistry
2004070
Method:
Immunohistochemistry
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 24 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Neuroendocrine
Test Name and Number Comments
Chromogranin A 0080469 Neuroendocrine cancer tumor marker
Method: Enzyme
Immunoassay
Chromogranin A by Neuroendocrine tumor marker
Immunohistochemistry
2003830
Method:
Immunohistochemistry
Pan Cytokeratin Neuroendocrine tumor marker
(AE1,3) by
Immunohistochemistry
2003433
Method:
Immunohistochemistry
Adrenocorticotropic Neuroendocrine tumor marker
Hormone (ACTH) by
Immunohistochemistry
2003427
Method:
Immunohistochemistry
Calcitonin by Neuroendocrine tumor marker
Immunohistochemistry
2003481
Method:
Immunohistochemistry
Growth Hormone by Neuroendocrine tumor marker
Immunohistochemistry
2003929
Method:
Immunohistochemistry
Insulin by Neuroendocrine tumor marker
Immunohistochemistry
2003972
Method:
Immunohistochemistry
Ki-67 Tissue Assay, Neuroendocrine tumor marker
Paraffin 0049270
Method:
Immunohistochemistry
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 25 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 26 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 27 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 28 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Lung
Test Name and Number Comments
Neuron Specific Enolase SCLC tumor marker
0098198
Method: Enzyme-Linked
Immunosorbent Assay
Chromogranin A 0080469 SCLC tumor marker
Method: Enzyme
Immunoassay
Cytokeratin 19 Fragment SCLC tumor marker
(CYFRA 21-1), Serum
0081344
Method: Enzyme-Linked
Immunosorbent Assay
Soluble Mesothelin Mesothelioma marker
Related Peptides
®
(MESOMARK ) 0081284
Method: Enzyme-Linked
Immunosorbent Assay
CDX2 by Lung tumor marker
Immunohistochemistry
2003821
Method:
Immunohistochemistry
Cytokeratin 19 (CK 19) Lung tumor marker
by Immunohistochemistry
2003845
Method:
Immunohistochemistry
Carcinoembryonic Lung tumor marker
Antigen, Monoclonal
(CEA M) by
Immunohistochemistry
2003824
Method:
Immunohistochemistry
Carcinoembryonic Lung tumor marker
Antigen, Polyclonal
(CEA P) by
Immunohistochemistry
2003827
Method:
Immunohistochemistry
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 29 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 30 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Method:
Immunohistochemistry
Thyroid Transcription Lung tumor marker
Factor (TTF-1) by
Immunohistochemistry
2004166
Method:
Immunohistochemistry
Human Chorionic Lung tumor marker
Gonadotropin (Beta-hCG)
by Immunohistochemistry
2003920
Method:
Immunohistochemistry
Female Gynecologic/Genitourinary
Test Name and Number Comments
ERBB2 (HER-2/neu) Breast cancer tumor marker (test is graded 0-3 in a semi-quantitative manner)
(4B5) Tissue Assay,
Paraffin 2002218
Method:
Immunohistochemistry
ERBB2 (HER-2/neu) Breast cancer tumor marker (test is graded 0-3 in a semi-quantitative manner)
(4B5) with Reflex to
ERBB2 (HER-2/neu)
Gene Amplification by
FISH if 2+ 2002217
Method:
Immunohistochemistry
HER-2/neu (PATHWAY )
® Breast cancer tumor marker (test is graded 0-3 in a semi-quantitative manner)
(4B5) with Reflex to FISH
if 2+ or 3+ 2002216
Method:
Immunohistochemistry
ERBB2 (HercepTest®) Breast cancer tumor marker (test is graded 0-3 in a semi-quantitative manner)
Tissue Assay, Paraffin
0049174
Method:
Immunohistochemistry
ERRB2 (HER-2/neu) Breast cancer tumor marker
Gene Amplification by
FISH 0049218
Method: Fluorescence in
situ Hybridization
ERBB2 (HER-2/neu) Breast cancer tumor marker
Gene Amplification by
CISH 2002443
Method: Chromogenic in
situ Hybridization
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 31 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 32 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Method:
Immunohistochemistry
Cytokeratin 20 (CK 20) Breast cancer tumor marker
by Immunohistochemistry
2003848
Method:
Immunohistochemistry
PIK3CA Mutation Breast cancer tumor marker
Detection 2004510
Method:
Polymerase Chain
Reaction/Pyrosequencing
Alpha-1-Fetoprotein (AFP) Germ cell tumor marker
by Immunohistochemistry
2003436
Method:
Immunohistochemistry
Breast Carcinoma b72.3 Breast cancer tumor marker
by Immunohistochemistry
2003445
Method:
Immunohistochemistry
Myeloperoxidase (MPO) Breast cancer tumor marker
by Immunohistochemistry
2004014
Method:
Immunohistochemistry
Cancer Antigen-Breast Breast cancer tumor marker
(CA 15-3) 0080464
Method:
Electrochemiluminescent
Immunoassay
Cancer Antigen 27.29 Breast cancer tumor marker
0080392
Method:
Chemiluminescent
Immunoassay
Carcinoembryonic Antigen Breast cancer tumor marker
0080080
Method:
Electrochemiluminescent
Immunoassay
Ki-67 Tissue Assay, Breast cancer tumor marker
Paraffin 0049270
Method:
Immunohistochemistry
HER-2/neu Quantitative Breast cancer tumor marker
by ELISA 2004672
Method: Enzyme-Linked
Immunosorbent Assay
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 33 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 34 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 35 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Method:
Immunohistochemistry
CD8 by Bladder cancer tumor marker
Immunohistochemistry
2003520
Method:
Immunohistochemistry
Male Genitourinary
Test Name and Number Comments
Prostate Specific Antigen, Prostate cancer tumor marker
Ultrasensitive 0098581
Method:
Electrochemiluminescent
Immunoassay
Prostate Specific Antigen, Prostate cancer tumor marker
Total with Reflex to Free
PSA
(Includes Free
Percentage) 0080264
Method:
Electrochemiluminescent
Immunoassay
PIK3CA Mutation Prostate cancer tumor marker
Detection 2004510
Method:
Polymerase Chain
Reaction/Pyrosequencing
Prostate Specific Antigen, Marker for recurrence after radical prostatectomy
0070121
Method:
Electrochemiluminescent
Immunoassay
PCA3 - Prostate Cancer Prostate cancer tumor marker; use if PSA is >10 ng/mL and biopsy negative
Biomarker 2001999
Method:
Transcription-mediated
Amplification/
Hybridization Protection
Assay
Bladder Tumor Associated Urine-based bladder cancer tumor marker
Antigen 8100500
Method: Qualitative
Immunoassay
®
NMP22 0080281 Male bladder cancer tumor marker
Method: Enzyme
Immunoassay
UroVysion
™
FISH Urine-based bladder cancer tumor marker
8100600
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 36 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Method:
Fluorescence in situ
Hybridization/Automated
Image Analysis
or Manual Screening
Beta-hCG, Quantitative Testicular cancer (germ cell) tumor marker
(Tumor Marker) 0070029
Method:
Chemiluminescent
Immunoassay
Alpha Fetoprotein, Serum Testicular cancer (germ cell) tumor marker
(Tumor Marker) 0080428
Method:
Electrochemiluminescent
Immunoassay
Ki-67 Tissue Assay, Bladder cancer tumor marker
Paraffin (Mib-1) 0049270
Method:
Immunohistochemistry
p53 Tissue Assay, Paraffin Bladder cancer tumor marker
0049250
Method:
Immunohistochemistry
Placental Alkaline Testicular cancer (germ cell) tumor marker
Phosphatase (PLAP) by
Immunohistochemistry
2004097
Method:
Immunohistochemistry
Human Chorionic Testicular cancer (germ cell) tumor marker
Gonadotropin (Beta-hCG)
by Immunohistochemistry
2003920
Method:
Immunohistochemistry
p16 by Bladder cancer tumor marker
Immunohistochemistry
2004064
Method:
Immunohistochemistry
p21, WAF, CIP1 by Bladder cancer tumor marker
Immunohistochemistry
2004067
Method:
Immunohistochemistry
p27 by Bladder cancer tumor marker
Immunohistochemistry
2004070
Method:
Immunohistochemistry
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 37 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Brain
Test Name and Number Comments
1p/19q Deletion by FISH Oligodendroglioma marker
0049360
Method: Fluorescence in
situ Hybridization
Neurofilament by Brain tumor marker
Immunohistochemistry
2004049
Method:
Immunohistochemistry
PIK3CA Mutation Brain tumor marker
Detection 2004510
Method:
Polymerase Chain
Reaction/Pyrosequencing
CD68, KP1 by Glioma tumor marker
Immunohistochemistry
2003598
Method:
Immunohistochemistry
Soft Tissue/Sarcomas
Test Name and Number Comments
EWSR1 (22q12) Gene Ewing sarcoma tumor marker
Rearrangement by FISH
0049335
Method: Fluorescence in
situ Hybridization
SYT-SSX t(X;18) Sarcomas tumor marker
Translocations by
RT-PCR 0040114
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 38 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Method: Reverse
Transcription
Polymerase Chain
Reaction/Fluorescence
Monitoring
SS18 (SYT) (18q11) Gene Sarcomas tumor marker
Rearrangement by FISH
0049380
Method: Fluorescence in
situ Hybridization
Kaposi Sarcomas tumor marker
Sarcoma-Associated
Herpesvirus/Human
Herpesvirus 8 0055629
Method:
Polymerase Chain
Reaction/Fluorescence
Monitoring
Herpes Virus 8 by Kaposi sarcoma tumor marker
Immunohistochemistry
2003932
Method:
Immunohistochemistry
Wilms Tumor (WT-1), Sarcomas tumor marker
N-terminus by
Immunohistochemistry
2004184
Method:
Immunohistochemistry
Myogenin (Myf4) by Rhabdomyosarcoma tumor marker
Immunohistochemistry
2004017
Method:
Immunohistochemistry
Myoglobin by Rhabdomyosarcoma tumor marker
Immunohistochemistry
2004031
Method:
Immunohistochemistry
Myosin by Rhabdomyosarcoma tumor marker
Immunohistochemistry
2004034
Method:
Immunohistochemistry
PAX-FKHR Translocation Rhabdomyosarcoma tumor marker
by RT-PCR 0040113
Method: Reverse
Transcription
Polymerase Chain
Reaction/Fluorescence
Monitoring
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 39 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Lymphoma
Test Name and Number Comments
IGH-BCL2 (BCL-2/JH) Non-Hodgkin lymphoma (NHL) tumor marker
Translocation, t(14;18) by
PCR, Fluid 0055616
Method: Polymerase
Chain Reaction
IGH-CCND1 (BCL-1/JH) NHL tumor marker
Translocation, t(11;14) by
PCR, Fluid 0055557
Method: Polymerase
Chain Reaction
Chromosome FISH, Monitor disease and identify specific abnormalities suspected clinically
Interphase 2002298 Specific FISH probes must be requested – ARUP Oncology FISH Probes menu
Method: Fluorescence in
situ Hybridization
BIRC2-MALT1 Tumor marker for leukemia lymphoma phenotyping and mucosa-associated
(AP12-MALT1) lymphoid tissue lymphoma (MALT)
Translocation, t(11;18) by
RT-PDR 0055691
Method: Reverse
Transcription Polymerase
Chain Reaction
IGH-CCND1 Fusion, Lymphoma classification/identification tumor marker
t(11;14) by FISH 0049381
Method: Fluorescence in
situ Hybridization
MYC (8q;24) Gene Burkitt lymphoma tumor marker
Rearrangement by FISH
2002345
Method: Fluorescence in
situ Hybridization
CD117 (c-Kit) by Lymphoma tumor marker
Immunohistochemistry
2003806
Method:
Immunohistochemistry
Octamer Transcription Lymphoma tumor marker
Factor-2 (Oct-2) by
Immunohistochemistry
2004061
Method:
Immunohistochemistry
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 40 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 41 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 42 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Method:
Immunohistochemistry
CD3 by Lymphoma tumor marker
Immunohistochemistry
2003508
Method:
Immunohistochemistry
CD4 by Lymphoma tumor marker
Immunohistochemistry
2003511
Method:
Immunohistochemistry
CD19 by B-cell lymphoma tumor marker
Immunohistochemistry
2005114
Method:
Immunohistochemistry
CD138 (Syndecan-1) by Lymphoma tumor marker
Immunohistochemistry
2003812
Method:
Immunohistochemistry
T-cell Intracytoplasmic Lymphoma tumor marker
Antigen (TIA-1) by
Immunohistochemistry
2004148
Method:
Immunohistochemistry
Epstein-Barr Virus (EBV) Lymphoma tumor marker
By in situ Hybridization,
Paraffin 2002902
Method: In situ
Hybridization
Leukemia
Test Name and Number Comments
Chromosome FISH, Chronic lymphocytic leukemia (CLL) tumor marker
CLL Panel 2002295
Method: Fluorescence in
situ Hybridization
Chromosome FISH, Monitor disease and identify specific abnormalities suspected clinically
Interphase 2002298 Specific FISH probes must be requested – ARUP Oncology FISH Probes menu
Method: Fluorescence in
situ Hybridization
TCF3-PBX1 (E2A-PBX1) Acute lymphocytic leukemia (ALL) tumor marker
Translocation, t(1;19) by
RT-PCR 0055346
Method: Reverse
Transcription
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 43 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Polymer/Polymerase
Chain Reaction
ETV6-RUNX1 AML tumor marker
(TEL-AML1)
Translocation, t(12;21) by
RT-PCR 0056008
Method: Reverse
Transcription Polymerase
Chain Reaction
RUNX1-RUNX1T1 Acute myelogenous leukemia (AML) tumor marker
(AML1-ETO)
Translocation, t(8;21) by
RT-PCR 0050444
Method: Reverse
Transcription Polymerase
Chain Reaction
CBFB-MYH1, inv(16) by AML tumor marker
RT PCR 0092209
Method: Reverse
Transcription Polymerase
Chain Reaction
PML/RARα FISH 2002363 AML tumor marker
Method: Fluorescence in
situ Hybridization
ZAP-70 Analysis by Flow AML tumor marker
Cytometry 0092392
Method: Flow Cytometry
BCR-ABL1 Kinase Tumor marker to monitor drug therapy for CML and ALL
Domain Mutation Analysis Detects >90% of mutations that may lead to imatinib resistance
0040138
Method:
Polymerase Chain
Reaction/Sequencing
BCR-ABL1, Major (p210), Tumor marker for CML and ALL therapy
Quantitative 2005017
Method: Reverse
Transcription/Quantitative
Polymerase Chain
Reaction
BCR-ABL1, Minor (p190), Tumor marker for CML and ALL therapy
Quantitative 2005016
Method: Reverse
Transcription/Quantitative
Polymerase Chain
Reaction
BCR-ABL1, T315I Tumor marker for CML and ALL therapy
Mutation Detection,
Quantitative 2004924
Method: Reverse
Transcription
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 44 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Polymerase Chain
Reaction/Pyrosequencing
BCR-ABL1, Major (p210), Tumor marker for CML and ALL therapy
Quantitative 2005010
Method: Reverse
Transcription Polymerase
Chain Reaction
PIK3CA Mutation Leukemia tumor marker
Detection 2004510
Method:
Polymerase Chain
Reaction/Pyrosequencing
CD117 (c-Kit) by Leukemia tumor marker
Immunohistochemistry
2003806
Method:
Immunohistochemistry
CD14 by Leukemia tumor marker
Immunohistochemistry
2003526
Method:
Immunohistochemistry
CD15, Leu M1 by Leukemia tumor marker
Immunohistochemistry
2003529
Method:
Immunohistochemistry
CD19 by B-cell leukemia tumor marker
Immunohistochemistry
2005114
Method:
Immunohistochemistry
CD20, L26 by Leukemia tumor marker
Immunohistochemistry
2003532
Method:
Immunohistochemistry
CD33 by AML tumor marker
Immunohistochemistry
2003553
Method:
Immunohistochemistry
CD56 (NCAM) by Leukemia tumor marker
Immunohistochemistry
2003589
Method:
Immunohistochemistry
Wilms Tumor (WT-1), Leukemia tumor marker
N-terminus by
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 45 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Immunohistochemistry
2004184
Method:
Immunohistochemistry
Pax-5 by Leukemia tumor marker
Immunohistochemistry
2004082
Method:
Immunohistochemistry
CD10 (CALLA) by Leukemia tumor marker
Immunohistochemistry
2003523
Method:
Immunohistochemistry
Cyclin D1, SP4 by Leukemia tumor marker
Immunohistochemistry
2003842
Method:
Immunohistochemistry
CD23 by Leukemia tumor marker
Immunohistochemistry
2003541
Method:
Immunohistochemistry
CD2 by Leukemia tumor marker
Immunohistochemistry
2003505
Method:
Immunohistochemistry
CD3 by Leukemia tumor marker
Immunohistochemistry
2003508
Method:
Immunohistochemistry
CD5 by Leukemia tumor marker
Immunohistochemistry
2003514
Method:
Immunohistochemistry
CD57 by Leukemia tumor marker
Immunohistochemistry
2003592
Method:
Immunohistochemistry
BCL-6 by Leukemia tumor marker
Immunohistochemistry
2003457
Method:
Immunohistochemistry
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 46 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Myeloproliferative Neoplasms
Test Name and Number Comments
JAK2 Gene, V617F Myeloproliferative neoplasms (MPN) tumor marker
Mutation, Quantitation
0040168
Method: Polymerase
Chain Reaction
JAK2 Gene, V617F MPN tumor marker
Mutation, Qualitative
0051245
Method: Polymerase
Chain Reaction
JAK2 Exon 12 Mutation MPN tumor marker
Analysis by PCR 2002357
Method: Polymerase
Chain Reaction
Childhood Tumors
Test Name and Number Comments
Neuron Specific Enolase 0098198 Marker for germ cell tumors
Method: Enzyme-Linked Immunosorbent Assay
MYCN (N-MYC) Gene Amplification by FISH 0049235 Neuroblastoma (childhood tumors) tumor marker
Method: Fluorescence in situ Hybridization
Homovanillic Acid (HVA), Urine 0080422 Neuroblastoma (childhood tumors) tumor marker
Method: High Performance Liquid Chromatography
Vanillylmandelic Acid (VMA) & Homovanillic Acid Neuroblastoma (childhood tumors) tumor marker
(HVA), Urine 0080470
Method: High Performance Liquid Chromatography
Catecholamines Fractionated by LC-MS/MS, Urine Neuroblastoma (childhood tumors) tumor marker
Free 0080407
Method: Tandem Mass Spectometry
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 47 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Skin
Test Name and Number Comments
S-100B Protein, Serum 2001766 Monitor treatment and determine prognosis in patients
Method: Enzyme-Linked Immunosorbent Assay with melanoma
NRAS Mutation Detection by Use in metastatic tumors to predict response to
Pyrosequencing 2003123 EGFR-directed therapy
Method: Polymerase Chain Reaction/Pyrosequencing
BRAF V600E Mutation Detection by PCR 2002498 Predict response to EGFR-directed therapy
Method: Polymerase Chain Reaction/Fluorescence
Monitoring
KIT Mutations, Melanoma 2002695 Predict response to EGFR-directed therapy
Method: Polymerase Chain Reaction/High Resolution
Melt Analysis
CD117 (c-Kit) by Immunohistochemistry 2003806 Melanoma tumor marker
Method: Immunohistochemistry
CD56 (NCAM) by Immunohistochemistry 2003589 Melanoma tumor marker
Method: Immunohistochemistry
Melan A by Immunohistochemistry 2003996 Melanoma tumor marker
Method: Immunohistochemistry
S-100 Protein by Immunohistochemistry 2004127 Melanoma tumor marker
Method: Immunohistochemistry
Melanoma Antibody, HMB45 by Melanoma tumor marker
Immunohistochemistry 2003935
Method: Immunohistochemistry
Human Chorionic Gonadotropin (Beta-hCG) by Melanoma tumor marker
Immunohistochemistry 2003920
Method: Immunohistochemistry
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 48 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Thyroid/Parathyroid
Test Name and Number Comments
Thyroglobulin, Serum or Thyroid cancer tumor marker
Plasma 0070421
Method:
Chemiluminescent
Immunoassay
Thyroglobulin Antibody Thyroid tumor marker
0050105
Method:
Chemiluminescent
Immunoassay
BRAF V600E Mutation Thyroid cancer tumor marker
Detection by PCR
2002498
Method:
Polymerase Chain
Reaction/Fluorescence
Monitoring
Thyroglobulin, Fine Thyroid tumor marker
Needle Aspiration (FNA)
0020753
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 49 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Method:
Chemiluminescent
Immunoassay
Parathyroid Hormone, Parathyroid cancer tumor marker
Intact with Calcium
0070172
Method:
Electrochemiluminescent
Immunoassay
Multiple Endocrine Hereditary thyroid cancer genetic marker
Neoplasia Type 2 (MEN2),
RET Gene Mutations by
Sequencing 0051390
Method:
Polymerase Chain
Reaction/Sequencing
Multiple Endocrine Hereditary thyroid cancer genetic marker
Neoplasia Type 2B (RET)
2 Mutations 0051492
Method:
Polymerase Chain
Reaction/Fluorescence
Monitoring
CDX2 by Thyroid/parathyroid tumor marker
Immunohistochemistry
2003821
Method:
Immunohistochemistry
Parathyroid Parathyroid tumor marker
Hormone (PTH) by
Immunohistochemistry
2004118
Method:
Immunohistochemistry
Muc-1 by Thyroid tumor marker
Immunohistochemistry
2004002
Method:
Immunohistochemistry
Muc-2 by Thyroid tumor marker
Immunohistochemistry
2004005
Method:
Immunohistochemistry
Muc-4 by Thyroid tumor marker
Immunohistochemistry
2004008
Method:
Immunohistochemistry
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 50 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Guidelines
NCCN Clinical Practice Guidelines. National Comprehensive Cancer Network. Fort Washington: Pennsylvania
[Accessed: 3 Feb 2011]
General References
Bakhshi S, Radhakrishnan V. Prognostic markers in osteosarcoma.Expert Rev Anticancer Ther. 2010; 10 (2) :271-287.
Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V. Tumor
markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.Ann Oncol. 2010; 21 (3)
:441-447.
McGuire BB, Fitzpatrick JM. Biomarkers in renal cell carcinoma.Curr Opin Urol. 2009; 19 (5) :441-446.
Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L. Systematic review of
the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt,
NMP22) and cytology for the detection and follow-up of bladder cancer.Health Technol Assess. 2010; 14 (4) :1-iv.
Na YJ, Farley J, Zeh A, del Carmen M, Penson R, Birrer MJ. Ovarian cancer: markers of response.Int J Gynecol
Cancer. 2009; 19 Suppl 2 :S21-S29.
Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer.Thyroid. 2009; 19 (12) :1351-1361.
O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape UF, Plockinger
U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical
markers.Neuroendocrinology. 2009; 90 (2) :194-202.
Ringel MD. Molecular markers of aggressiveness of thyroid cancer.Curr Opin Endocrinol Diabetes Obes. 2009; 16 (5)
:361-366.
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 51 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Philip
R, Ransohoff DF, Skates SJ, Regnier FE, Anderson NL, Mansfield E. Analytical validation of protein-based multiplex
assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics.Clin Chem.
2010; 56 (2) :237-243.
Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in
diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.Leuk Lymphoma. 2010;
51 (2) :199-212.
References from the ARUP Institute for Clinical and Experimental Pathology®
Bahler DW, Szankasi P, Kulkarni S, Tubbs RR, Cook JR, Swerdlow SH. Use of similar immunoglobulin VH gene
segments by MALT lymphomas of the ocular adnexa.Mod Pathol. 2009; 22 (6) :833-838.
Chernock RD, Perry A, Pfeifer JD, Holden JA, Lewis JS Jr. Receptor tyrosine kinases in sinonasal undifferentiated
carcinomas--evaluation for EGFR, c-KIT, and HER2/neu expression.Head Neck. 2009; 31 (7) :919-927.
Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF, Tripp SR, Rassidakis GZ,
Medeiros LJ, Szankasi P, Elenitoba-Johnson KS. The proteomic signature of NPM/ALK reveals deregulation of
multiple cellular pathways.Blood. 2009; 114 (8) :1585-1595.
Margraf RL, Calderon FR, Mao R, Wittwer CT. RET mutation scanning update: exon 15.Clin Chem. 2009; 55 (11)
:2059-2061.
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF,
Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk
predictor of breast cancer based on intrinsic subtypes.J Clin Oncol. 2009; 27 (8) :1160-1167.
Poirel HA, Cairo MS, Heerema NA, Swansbury J, Auperin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphael
M, McCarthy K, Sposto R, Gerrard M, Bernheim A, Patte C. Specific cytogenetic abnormalities are associated with a
significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the
FAB/LMB 96 international study.Leukemia. 2009; 23 (2) :323-331.
Slattery ML, Wolff RK, Herrick J, Caan BJ, Samowitz W. Tumor markers and rectal cancer: support for an
inflammation-related pathway.Int J Cancer. 2009; 125 (7) :1698-1704.
Reviewed by
Bahler, David W., MD, PhD. Medical Director, Hematologic Flow Cytometry at ARUP Laboratories; Associate
Professor of Pathology, University of Utah
Grenache, David G., PhD. Medical Director, Special Chemistry at ARUP Laboratories; Associate Professor of
Pathology (Clinical), University of Utah
Jarboe, Elke, MD. Assistant Medical Director, Immunohistochemistry and Cytopathology R&D at ARUP Laboratories;
Assistant Professor, Anatomic Pathology, University of Utah
Kelley, Todd, MD, MS. Co-Medical Director, Molecular Hematopathology at ARUP Laboratories; Assistant Professor of
Pathology, University of Utah
Layfield, Lester, MD. Fine-Needle Aspiration Services and Molecular Diagnostics at ARUP Laboratories; Professor
and Head, Surgical Pathology, University of Utah
Mao, Rong, MD. Medical Director, Molecular Genetics, Fragment Analysis and Sequencing at ARUP Laboratories;
Assistant Professor of Pathology (Clinical), University of Utah
Meikle, A. Wayne, MD. Medical Director, RIA and Endocrinology at ARUP Laboratories; Professor of Internal Medicine
and Pathology, University of Utah
Prchal, Josef T., MD. Medical Director, Special Genetics at ARUP Laboratories; Professor of Hematology, Pathology
and Genetics, University of Utah
Roberts, William L., MD, PhD. Medical Director, Automated Core Laboratory at ARUP Laboratories; Professor of
Pathology, University of Utah
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 52 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
Samowitz, Wade S., MD. Medical Director, AP Oncology at ARUP Laboratories; Professor of Pathology, University of
Utah
South, Sarah T., PhD. Medical Director, Cytogenetics and Molecular Cytogenetics at ARUP Laboratories; Assistant
Professor, Department of Pediatrics, Adjunct Professor, Department of Pathology, University of Utah
Related Content
Acute Lymphoblastic Leukemia - ALL
Acute Myeloid Leukemia - AML
Bladder Cancer
Breast Cancer
Carcinoid Tumors
Central Nervous System Tumors - Brain Tumors
Cervical Cancer
Chronic Lymphocytic Leukemia - CLL
Chronic Myelogenous Leukemia - CML
Colorectal Cancer
Ewing Sarcoma
Glucagonoma
Hepatocellular Carcinoma
Human Papillomavirus - HPV
Insulinoma
Lung Cancer
Lymphoma Phenotyping
Lymphomas, B-Cell - B-Cell Lymphomas
Lymphomas, T/NK-Cell - T/NK-Cell Lymphomas
Lynch Syndrome - Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
Melanoma
Mesothelioma
Multiple Endocrine Neoplasias - MEN
Myeloproliferative Neoplasms - MPN
Neuroblastoma
Neuropathic Disease
Ovarian Cancer
Pancreatic Cancer
Pancreatic Neuroendocrine Tumors - NET
Paraneoplastic Neurological Syndromes
Pheochromocytoma
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 53 of 54
The Physician's Guide to Laboratory Test Selection and Interpretation
ARUP LABORATORIES | 500 Chipeta Way | Salt Lake City, Utah 84108-1221 | (800) 522-2787 | www.arupconsult.com | www.aruplab.com
© 2006–2011 ARUP Laboratories. All Rights Reserved. Tumor Markers - p. 54 of 54